Cspc Megalith Biopharmaceutical Co.,ltd.
Clinical trials sponsored by Cspc Megalith Biopharmaceutical Co.,ltd., explained in plain language.
-
New drug combo shows promise for tough head and neck cancers
Disease control Recruiting nowThis study tests two experimental drugs, SYS6010 and Enlonstobart, together in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors and control the disease. About 70 adults who have not had prior systemic treatment…
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated May 26, 2026 06:48 UTC
-
New hope for lung cancer patients: SYS6010 takes on chemo in major trial
Disease control Recruiting nowThis study compares a new drug, SYS6010, with standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to targeted pills (EGFR TKIs). About 380 adults aged 18-75 will be randomly assigned to receive either SYS6010 or…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New drug SYS6043 shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not improved with standard treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The goal is to find the safest dose and…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC